NOVOS Debuts Longevity Product Line, Leveraging Breakthrough Scientific Discoveries to Slow Down the Pace of Aging
Retrieved on:
Wednesday, May 10, 2023
Health, Other Health, General Health, Research, Vitamins, Supplements, Science, Acceleration, Cognition, Fourth Estate Public Benefit Corporation, DNA, Drink, NAD, Doctor of Philosophy, PBC, Professional corporation, Ageing, NMN, Multimedia, MIT, Life expectancy, Calcium alpha-ketoglutarate, Harvard Medical School, Cellular senescence, Capsule, Salk Institute for Biological Studies, DNA repair, Metabolism, Mortality, Longevity, Glycine, Pharmaceutical industry, Dietary supplement, NOVOS
After four years of rigorous testing and formulating, NOVOS is now unveiling its line of science-backed, patent-pending supplements for consumers that aim to slow down the pace of aging by targeting its root causes.
Key Points:
- After four years of rigorous testing and formulating, NOVOS is now unveiling its line of science-backed, patent-pending supplements for consumers that aim to slow down the pace of aging by targeting its root causes.
- The company has gone through multiple third-party research studies to assess the impact of its supplements on longevity and healthy aging.
- In in-vitro human cell studies, NOVOS supplements were shown to reduce DNA damage from irradiation by up to 77% and inhibit cellular senescence.
- As a Public Benefit Corporation (PBC), NOVOS is committed to educating consumers about healthy living, regularly publishing Ph.D. and M.D.-authored articles